Breakthrough Study On Biotin Offers Probable Cure For Multiple Sclerosis; Is There A Catch?

Long before, although its emergence remains to be a mystery, Multiple Sclerosis has been noted as an auto-immune disease wherein the immune system affects the central nervous system which includes the brain as well as the spinal cord. Many people that are inflicted with the disease are believed to use a balanced diet to help manage their symptoms, and vitamins are an essential component of this.

 In line with that, Biotin, which is sometimes referred to as Vitamin B7 or Vitamin H, is one of the B complex vitamins and is essential for human health, has recently been put to the spotlight after it has been considered as beneficial for MS patients. It was found that for those patients with progressive multiple sclerosis (MS) and their clinicians have seen clear improvements during treatment with a high dose of biotin.

Biotin Offers Probable Cure For Multiple Sclerosis

According to reports revealed by Medical News Today, the use of biotin is perceived as very useful especially in cases of progressive MS since it has the ability to support cell metabolism. A number of experts have explained that MS develops when myelin, a substance that protects the nerve cells, is damaged. In turn, biotin is known to be responsible in activating key enzymes and helps the body to produce more of this the nerve-protecting substance.

Breakthrough Study On Biotin

Meanwhile, as per News Medical Life Sciences, a study on biotin has found that the substance is allegedly a co-enzyme for several carboxylases, one of which is thought to have a key role in myelin synthesis. Presenter of the study Ayman Tourbah from CHU de Reims, France has noted that a significant number of physicians have scored patients receiving biotin (300 mg/day) between no change and much improved, whereas they were found to have scored those in the placebo group between no change and much or very much worse. Ultimately, Tourbah said that the findings reportedly confirm the clinical relevance of the trial's previously reported primary finding.


© 2022 iTech Post All rights reserved. Do not reproduce without permission.

More from iTechPost